Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 9
Submit an article Journal homepage
378
Views
0
CrossRef citations to date
0
Altmetric
Original Article: Research

DNA damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells

Hailong TangDepartment of Hematology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China;
,
Mimi ShuDepartment of Hematology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China;
,
Bo DaiShaanxi Center for Stem Cell Application Engineering Research, Xi’an, Shaanxi, China
,
Li XuDepartment of Hematology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China;
,
Baoxia DongDepartment of Hematology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China;
,
Guangxun GaoDepartment of Hematology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China;
&
Xiequn ChenDepartment of Hematology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China; Correspondence[email protected]
 show all
Pages 2220-2226 | Received 12 Sep 2017, Accepted 27 Nov 2017, Published online: 18 Dec 2017

References

  • Pan Y, Gao Y, Chen L, et al. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res. 2011;17:3248–3258.
  • Genadieva Stavric S, Bonello F, Bringhen S, et al. How is patient care for multiple myeloma advancing? Expert Rev Hematol. 2017;10:551–561.
  • Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4:2186–2207.
  • Pang J, Shi Q, Liu Z, et al. Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression. Haematologica. 2017;102:1273–1280.
  • Sun Y, Nelson PS. Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res. 2012;18:4019–4025.
  • Sun Y, Campisi J, Higano C, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18:1359–1368.
  • Zimmermann M, Arachchige-Don AS, Donaldson MS, et al. Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin. J Biol Chem. 2012;287:22838–22853.
  • Woods D, Turchi JJ. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther. 2013;14:379–389.
  • Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–1078.
  • Derheimer FA, Kastan MB. Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett. 2010;584:3675–3681.
  • Paull TT, Rogakou EP, Yamazaki V, et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol. 2000;10:886–895.
  • Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585–621.
  • Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–2868.
  • Rodier F, Coppe JP, Patil CK, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11:973–979.
  • Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143:355–366.
  • Marzo LD, Desantis V, Solimando AG, et al. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget. 2016;7:60698–60711.
  • Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9:665–674.
  • Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol. 2009;2:649–662.
  • Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Transl Med. 2017;6:1445–1451.
  • Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003;17:1175–1182.
  • Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 inparacrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630–2636.
  • Dong H, Chen L, Chen X, et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma. 2009;50:974–984.
  • Canino C, Mori F, Cambria A, et al. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene. 2012;31:3148–3163.
  • Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.